FDA converts emergency nod for Lilly’s Olumiant to a full approval for hospitalized COVID patientsnews2022-05-11T13:00:28+00:00May 11th, 2022|Fierce Pharma|
Moderna’s new CFO out the door after former employer discloses accounting probenews2022-05-11T12:56:41+00:00May 11th, 2022|Fierce Pharma|
Teva faces $100M lawsuit from Israel over unpaid Copaxone royalties: reportnews2022-05-11T11:50:28+00:00May 11th, 2022|Fierce Pharma|
Emergent destroyed up to 400M COVID-19 vaccines, far more than previously known: reportnews2022-05-10T18:13:56+00:00May 10th, 2022|Fierce Pharma|
Life Sciences Summit: Accelerating Growth at Emerging Biotechsnews2022-05-10T16:14:26+00:00May 10th, 2022|Fierce Pharma|
Pharma marketers, don’t throw away your TV ad plans just yetnews2022-05-10T15:16:05+00:00May 10th, 2022|Fierce Pharma|
Bayer’s pharma business feels the pain from Xarelto generics in Chinanews2022-05-10T14:16:57+00:00May 10th, 2022|Fierce Pharma|
Hovione’s drug delivery tech lands eye disease licensing dealnews2022-05-10T13:35:07+00:00May 10th, 2022|Fierce Pharma|
Pfizer buys migraine partner Biohaven for $11.6B, betting on CGRP drugs in grand return to neurosciencenews2022-05-10T13:10:04+00:00May 10th, 2022|Fierce Pharma|
ICER says Pfizer’s Paxlovid, Merck’s molnupiravir both cost effective, but their benefits are far from equalnews2022-05-10T13:00:30+00:00May 10th, 2022|Fierce Pharma|
